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INTRODUCTION
Recently, aging has become a familiar phenomenon around 
the world. Aging societies are faced with various chronic dis-
eases, such as Alzheimer’s disease (AD), obesity, and type 2 
diabetes (T2DM). Globally, an estimated 422 million adults 
over the age of 18 years suffered with diabetes in 2014, and 5.3 
million Americans of all ages were diagnosed with AD in 2015.1 
According to the 2012 Korean Epidemiological Survey of De-
mentia, around 530 thousands Koreans older than 65 years 
were diagnosed with AD, with an estimated two-fold increase 
therein every 20 years. Interestingly, obesity, T2DM, and AD are 
reported to be related with each other.2
AD is a degenerative brain disease and the most common 
cause of dementia. AD is characterized by extracellular amyloid 
beta (Aβ) plaques and intraneuronal deposits of neurofibrillary 
tangles (NFTs). NFTs are constituted by hyperphosphorylated 
tau proteins, whereas Aβ plaques are insoluble and aggregated 
form of Aβ peptide.3 Until now, therapeutics for AD has been 
focused mostly on Aβ, with little success. Development of AD 
treatment could potentially benefit from seeking to consider 
the relationships among AD, obesity, and T2DM.
According to the Mayo Clinic Alzheimer Disease Patient Reg-
istry, 80% of AD patients show impairment in glucose tolerance 
or have diabetes.4 Epidemiological studies have demonstrated 
that T2DM induces cognitive impairment and that patients 
with T2DM are more likely to be diagnosed with dementia by 
1.5- to 2-fold.5 Also, increasing evidence has shed light on cellu-
lar insulin resistance or insulin insufficiency in the brains of AD 
patients, including those without having diabetes, thus AD is 
often referred to as “type 3 diabetes”.6
Obesity is generally defined by a body mass index (BMI) over 
30 kg/m2 (25 kg/m2 in Korea) and is usually caused by physi-
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cal inactivity and westernized diet habits. Obesity is an impor-
tant risk factor for various diseases, ranging from metabolic 
diseases to neurodegenerative diseases. As obesity causes in-
sulin resistance, it is one of the major risk factor for T2DM. After 
years of hyperinsulinemia, insulin secretory function in the 
pancreas can falter, causing patients to suffer from relative hy-
poinsulinemia, which leads to hyperglycemia.7
A large number of research has proven that obesity in middle 
age individuals can be an index of mild cognitive impairment 
at later years.8 Even when controlling for aging, studies have 
shown a negative correlation between BMI and global cogni-
tive performance.9 T2DM has also been linked to reduced cog-
nitive function and an increased risk for developing dementia, 
including AD.10
AD, obesity, and T2DM share similar demographic profiles, 
risk factors, and clinical and biochemical features.11 These con-
ditions are associated with chronic inflammation, severe oxida-
tive stress, and impairment in insulin signaling and energy me-
tabolism.12 Interestingly, people with diets high in cholesterol, 
saturated fats, and total calories have been found to be at great-
er risk for AD than people who regularly eat fiber, vegetables, 
and fruits.13 Animal studies have also demonstrated that a high-
fat diet causes AD pathology, including accumulation of Aβ and 
phosphorylated tau proteins, as well as cognitive impair-
ment.14,15
Given the relationship among obesity, T2DM, and AD, un-
derstanding the mechanistic links among them is essential to 
developing effective strategies for AD prevention and treat-
ment. Until now, inflammation has been thought to link obesi-
ty, T2DM, and AD.1,16 Considering AD as a metabolic disease, 
however, we suggest that metabolic alterations could be the 
primary mechanistic links among these diseases. Therefore, 
the specific goal of this review paper was to investigate proper 
therapeutic targets for treating AD from our point of view that 
AD is a metabolic disease.
ALZHEIMER’S DISEASE: METABOLIC 
ALTERATIONS IN THE BRAIN
AD is a degenerative disease that impairs cognition and mem-
ory and is a leading cause of dementia. Alois Alzheimer, for 
whom AD is named, described the pathology of the disease as 
an extensive distribution of neuronal tangles and amyloid pl-
aques in the brain, which are considered hallmarks of the dis-
ease.3 Aβ accumulation is thought to initiate AD by destroying 
synapses causing neuron loss, a process known as amyloid hy-
pothesis. Amyloid hypothesis has become the dominant mod-
el of AD pathogenesis and has guided the development of po-
tential treatments for AD.17
However, clinical studies have documented several incon-
sistencies in AD pathology. Around 99.6% of drug candidates 
targeting amyloid pathways, such as beta secretase inhibitors, 
gamma secretase inhibitors, and Aβ itself, have failed.18 In ad-
dition, a weak correlation between Aβ deposition and cognitive 
decline have been reported.19 For example, Aβ deposits are ob-
served in the medial prefrontal cortex at early stages of AD. 
Then, these deposits expand into the medial temporal lobe, in-
cluding the hippocampus. However, cognitive function begins 
to decline in an opposite way, starting from the medial tem-
poral lobe to the medial prefrontal cortex.20
Recently, early selective atrophy and alteration of glucose me-
tabolism were discovered in the medial temporal lobe of pa-
tients with AD using imaging tools.21 In addition, in Alzheimer’s 
disease, degeneration of the basal forebrain cholinergic neurons 
and a decrease in brain glucose metabolism are characteristi-
cally observed.22 With two functional brain imaging techniques, 
the [18F] 2-fluoro-2-deoxy-D-glucose positron emission tomog-
raphy and functional magnetic resonance imaging, alterations 
of glucose metabolism in the brain have begun to receive atten-
tion as a feasible cause for AD.23 Interestingly, patients with AD 
have been found to display increased lactate levels in cerebro-
spinal fluid (CSF), resulting from metabolic dysfunction;24 how-
ever, this type of metabolic alteration has only now been consid-
ered as a characteristic of AD.
Aging plays critical roles in neurodegenerative disease and 
metabolism and is an important cause of AD. As an individual’s 
metabolism gets weaker with age, metabolic alterations are fea-
sible consequences of aging and potential causes of AD. In-
deed, imaging studies have shown that a person aged over 70 
years could have presymptomatic AD if individuals exhibit dys-
regulation in glucose metabolism, even though they may show 
normal cognition at present.25 However, amyloid hypothesis 
considers AD as a disease determined exclusively by the ge-
nomic instability not by metabolic alterations.26
There are two types of cells in the brain, neuron and glial cells, 
and they are reported to be related with many components of 
metabolism, called neuron-astrocyte shuttle hypothesis.27 Both 
cells make use of glucose as a primary energy source, although 
they metabolize glucose in different ways. In astrocytes, most 
glucose is metabolized to lactate anaerobically, and then, lactate 
is released into the extracellular space. In neurons, pyruvate de-
rived from glucose or lactate is metabolized under aerobic con-
ditions, and the energy is produced mainly by oxidative phos-
phorylation in the mitochondria. Because neurons do not have 
enough activated glycolysis prompting enzymes, neurons are 
inclined to not process glucose through glycolysis.28
Due to aging, mitochondria can malfunction, resulting in ex-
cessive increases in oxidative stress, as well as oxidative phos-
phorylation, in the brain.29 Increased mitochondrial oxidative 
activity demands more energy substrates to produce energy, 
such that there is an energy shortage in the whole body even 
though the other cells that have not experienced increased 
oxidative activity including the brain suffer energy shortage.30 
Thereby, some neurons are unable to occupy energy substrates 
and produce enough energy. Lacking energy, these neurons 
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cannot survive and cause dementia.
Metabolic diseases, such as T2DM and obesity, are reported 
to be related with AD, meaning that AD is a kind of metabolic 
disease (Fig. 1). Therefore, metabolic alteration could be poten-
tial cause of AD, such that various substances (insulin, adipo-
nectin, and antioxidants) that are influenced by metabolic al-
terations could be therapeutic targets for AD.
ALZHEIMER’S DISEASE: BRAIN INSULIN 
RESISTANCE
Considering the prevalences with which T2DM and AD occur, 
the idea that patients with T2DM could be at higher risk for AD 
has garnered greater acceptance. In addition, patients with 
T2DM have been found to be at a two-fold higher risk for AD 
and to be diagnosed with mild cognitive impairment in a com-
parably shorter time.31 Hyperglycemia has also been found to 
accelerate cognitive decline.32 As the brain is likely to encoun-
ter defective insulin signaling with increasing age,33 research-
ers have begun to study mechanistic links between these dis-
eases; the most promising link has been insulin.34
Insulin is a major anabolic hormone that is secreted from 
pancreas beta cells in response to high glucose levels. Insulin 
signals by binding to insulin receptors, thereby activating insu-
lin receptor substrate 1, extracellular signal-related kinase/mi-
togen activated protein kinase, and PI3 kinase/Akt pathways. 
Insulin also inhibits glycogen synthase kinase-3 (GSK-3).35 
Through these signals, insulin maintains glucose homeostasis 
by regulating glucose production from the liver and glucose 
consumption by muscle and adipose tissue via GLUT4 trans-
location. Accordingly, impairment of insulin secretion or func-
tion is considered a primary cause of diabetes.36
Insulin resistance refers to the reduced ability of insulin on 
target tissues, including liver, muscle, and fat tissues. Specifi-
cally, insulin receptors’ ability to transmit downstream signals 
or the ability of insulin to activate insulin receptors are reduced 
in insulin responsive tissues, and these phenomena have been 
considered as a hallmark feature of T2DM.37 While the vital role 
of insulin in the periphery is well recognized and has been ex-
tensively studied, the function of insulin in the central nervous 
system has only recently been studied.
Due to the large size of insulin peptide, it was thought that 
insulin is unable to cross the brain blood barrier (BBB), such 
that the brain was regarded as an insulin-independent organ.38 
However, several studies have revealed that insulin receptors 
are abundantly distributed throughout the brain, proposing 
some mechanisms to explain the existence of insulin in the 
brain.39 Currently, insulin has been shown to be transported 
across the BBB through a carrier-mediated, saturable, and tem-
perature-sensitive active process.40
All tissues and cell types, including neurons, have conserved 
insulin-signaling pathways.41 As shown in Fig. 2A, insulin partici-
pates in neuromodulation to regulate the concentrations of neu-
rotransmitters, such as acetylcholine,42 repair, neuronal differen-
tiation, proliferation, regeneration, and inhibition of neuronal 
apoptosis.43 Through downstream cascade, insulin mediates 
long-term potentiation, learning, and memory processes.44,45 In-
sulin signaling in specific brain regions, such as the limbic system 
and hypothalamus, has been found to be necessary for cognitive 
function.46
Interestingly, patients with diabetes also show insulin resis-
tance in the brain.47 As Fig. 2B describes, reduced insulin action 
causes AD like alterations in the brain.48 In turn, Aβ oligomers 
initiate to remove insulin receptors from plasma membranes.49 
Following these discoveries, insulin has been measured in 
postmortem brain tissue from AD patients, showing relatively 
low levels of insulin.50 Previously, we demonstrated that long-
term high fat diet induces T2DM with insulin resistance both 
in the body and the brain, as well as AD pathologies, such as 
cognitive defects, accumulation of Aβ, and hyperphosphory-
lated tau in ICR mice.51
Fig. 1. Alteration of brain metabolism causes Alzheimer’s disease. Aging and metabolic diseases, such as obesity and diabetes, can alter brain me-
tabolism. Alteration of brain metabolism progressively causes Alzheimer’s disease.
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Insulin affects Aβ accumulation and the phosphorylation of 
tau as well. Insulin-degrading enzyme (IDE) is known to de-
grade excess insulin and other substrates, such as Aβ (Fig. 2). 
IDE knockout mice display accumulation of Aβ, hyperinsu-
linemia, and hyperglycemia.52 As insulin levels are raised, IDE 
expression is activated to prevent the long-term activation of in-
sulin. However, when IDE is occupied with excess insulin, IDE 
cannot degrade Aβ, leading to the formation of senile plaques.53
GSK-3 has been most extensively studied as a kinase for tau, 
although it is also involved in Aβ production.54 GSK-3 is a multi-
functional serine/threonine kinase that is affected by both the 
phosphorylation and aggregation of tau. One study has re-
vealed that inhibition of GSK-3 improves learning and memory 
and decreases phosphorylation of tau in AD transgenic mouse 
models.55 We also demonstrated that GSK-3 is inhibited in the 
brain of mice with AD pathologies.51
Notably, intranasal administration of insulin has been found 
to help normal adults with improved memory by maintaining 
their serum insulin and glucose levels.56 Furthermore, intrana-
sal insulin treatment has been shown to enhance cognitive 
performance in early AD patients,57 suggesting that insulin 
could be therapeutic target for AD.
ALZHEIMER’S DISEASE: REDUCED 
LEVELS OF ADIPONECTIN INDUCED 
BY OBESITY
The incidence of obesity is steadily rising throughout the 
world.58 Obesity can have damaging effects on many organ sys-
tems,59 because many changes induced by obesity are related 
to metabolic syndrome, characterized by excess weight, high 
triglyceride levels, and insulin resistance. Moreover, the inci-
dences of cognitive decline and AD are increased with obesity.60
In normal adipose tissue, adipocytes secrete bioactive mol-
ecules, termed adipokines, including leptin, and adiponectin.61 
Adipokines regulate several important physiological func-
tions: for example, appetite, satiety, energy expenditure, insu-
lin sensitivity and secretion, glucose and lipid metabolism, fat 
distribution, hemostasis, blood pressure, neuroendocrine reg-
ulation, and function of the immune system.62
In obesity, adipocytes become bigger, and hypertrophic ad-
ipocytes lead to the development of a pro-inflammatory envi-
ronment. Hypertrophic adipocytes are often necrotic, and in-
filtration of macrophages is increased. Activated macrophages 
gather around necrotic adipocytes, where they secrete pro-in-
flammatory cytokines, such as TNF-α, IL-1β. This condition 
has systemic effects and is linked with the initiation of T2DM 
pathology.63
Among adipokines, adiponectin has beneficial effects on 
patients with T2DM and has been used in T2DM treatment 
due to its role of increasing insulin sensitivity.64 Adiponectin 
has been shown to enhance insulin sensitivity and several 
studies have reported the relationship between an increased 
prevalence of diabetes and decreased levels of adiponectin.65 
Overexpression of adiponectin prevents high-fat diet-induced 
obesity in rodents, and genetically eliminating adiponectin in 
obese mice facilitates increased fat in the liver.66 Adiponectin 
reduces hepatic lipogenesis and increases β-oxidation through 
adiponectin receptor 1 (adipoR1)-mediated activation of ade-
Fig. 2. Brain insulin resistance causes Alzheimer’s disease. (A) Insulin signaling maintains normal neuronal functions through IRS, ERK/MAPK, PI3K/
AKT, and GSK3 signals. (B) Brain insulin resistance blunts insulin signal transduction, leading to neuronal cell death and Alzheimer’s disease. IRS, in-
sulin receptor substrate; ERK/MAPK, extracellular signal-related kinase/mitogen activated protein kinase; PI3K/AKT, PI3 kinase/Akt pathways; GSK3, 
glycogen synthase kinase-3; IDE, insulin-degrading enzyme; Aβ, amyloid beta.
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nosine monophosphate kinase (AMPK) and peroxisome pro-
liferator-activated receptor α (PPAR α).67
While many researchers have maintained that adiponectin 
cannot cross the BBB, adiponectin is observed in CSF, and re-
ceptors for adiponectin are observed in the brain, suggesting 
the existence of adiponectin in the brain.68 As shown in Fig. 3A, 
adiponectin functions in the brain like insulin. As adiponectin 
receptors are expressed widely in the brain, including the hypo-
thalamus, brainstem, cortex, and pituitary gland, adiponectin 
signaling pathways are activated in the brain and regulate ener-
gy expenditure, food intake, inflammation, cell death, and pro-
tection.69
Recently, the relationship between adiponectin and AD has 
begun to be studied. Some researchers have found a positive 
correlation between plasma and CSF adiponectin levels. Pa-
tients with mild cognitive impairment or AD have significantly 
higher plasma and CSF adiponectin levels than aged controls.70 
However, some researchers found no significant differences in 
the plasma adiponectin levels between AD patients and non-
AD controls. The exact relationship between adiponectin levels 
and the occurrence of AD remains unclear, although ongoing 
research suggests a complex association between AD and adi-
ponectin.71
Because AMPK acts as a general energy sensor in the CNS,72 
inhibition of adiponectin could affect brain metabolism (Fig. 
3B). The local up-regulation of hypoxia inducible factor-1α 
(HIF-1α) in adipocytes in obese individuals is induced by hy-
poxic environment due to hypertrophic adipocytes.73 A study 
found that HIF-1α inhibits production of adiponectin. When 
adipocyte-specific HIF-1α knock-out mice were fed a high-fat 
diet for 7 weeks, they displayed high levels of adiponectin 
mRNA; meanwhile, control mice showed significantly low 
levels of adiponectin mRNA.74 These conditions could induce 
metabolic alteration in the brain and initiate pathology of AD.
As we mentioned above, a high fat diet can induce AD pa-
thologies.14,15 To find a connection among HIF-1α, adiponectin, 
and AD, we fed a 60% high fat diet to 8 weeks old ICR mice for 
24 weeks. These obese mice displayed cognitive decline and 
accumulation of Aβ and phosphorylated tau in the brain (under 
submission). We also revealed that 24 weeks of a high fat-diet 
induces reductions in the amounts of adiponectin and adipoR1, 
as well as increase in HIF-1α, in the brain, especially the cortex 
(Fig. 4).
Even though glucose and lactate are known as major energy 
sources in the brain, they are not enough to satisfy the energet-
ic demands of the brain. A study revealed that the amount of 
glucose consumption and the levels of oxygen utilization in 
the brain are not matched.75 In terms of lactate, large amounts 
Fig. 3. Reduced adiponectin levels induce brain metabolism alterations and consequently Alzheimer’s disease. (A) Healthy adipose cells release adi-
ponectin actively. Adiponectin regulates glucose metabolism and oxidases fatty acids in the brain in normal conditions. (B) Hypertrophic adipose 
cells induced by obesity elicit a pro-inflammatory environment and reduce adiponectin production. Reduced adiponectin causes energy shortages in 
the brain due to reduced fatty acid oxidation and dysregulated glucose metabolism. This induces brain metabolism alterations and progressively 
leads to Alzheimer’s disease. HIF 1α, hypoxia inducible factor 1α.
A
B
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of lactate are unable to generate energy, because cells remove 
lactate very well and tissues that generate lactate consume 
most of it.76
After these discoveries, researchers found that fatty acids can 
enter the brain and mitochondria can oxidize them in the 
brain.77 Even though some studies have revealed that fatty acids 
are unable to be used as fuels for brain energy, mitochondrial 
oxidation of fatty acids provide energy to the brain, maximally 
20% of its total energy.78 Furthermore, fatty acids play important 
roles in glucose homeostasis.79 Fatty acid metabolism is related 
with adiponectin, so that alterations of adiponectin could in-
duce brain metabolism alteration and AD. Furthermore, adipo-
nectin could be a potential therapeutic target for AD.
POSSIBLE CAUSE OF ALZHEIMER’S 
DISEASE: REDUCED ANTIOXIDANT 
DEFENSE MECHANISMS INDUCED 
BY VARIOUS METABOLIC ALTERATIONS
Reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) are defined as reactive chemicals that have the capacity 
to donate electrons (e-) to various molecules.80 In cells, ROS/
RNS are produced through normal metabolism under aerobic 
physiological conditions.81 These species are generated under 
not only normal but also pathological conditions and result in 
oxidative stress, including nitrogen-based free radical species, 
as well as superoxide free radicals and hydrogen peroxide.82
Physiological levels of ROS/RNS play an important role in 
maintaining homeostasis and regulating signal transduction 
involved in proliferation and survival.83 Cellular antioxidant 
defense mechanisms regulate ROS/RNS production to main-
tain proper amounts thereof in normal environments. Howev-
er, when ROS/RNS formation is dysregulated, oxidative stress 
disrupts cellular function and damages cells.82,84
Research indicates that Aβ causes oxidative stress. Aβ can 
form complexes with copper (Cu), generating hydrogen perox-
ide via Cu2+reduction.85 Aβ-induced oxidative stress disturbs 
cellular signaling and initiates a phosphorylation response, re-
sulting in activated JNK, p38 MAPK, and hyperphosphorylated 
tau proteins in AD postmortem brains.86 Furthermore, since Aβ 
is generated from the cleavage of amyloid precursor proteins, 
located in trans membrane, it inserts into the bilayer of cells 
and initiates lipid peroxidation and a series of reactions, pro-
ducing ROS.87
ROS levels are increased in obesity.88 Many studies have dem-
onstrated that reduced insulin signals and adipokines dysregu-
lation in T2DM patients leads to increased ROS production.89 
Furthermore, high glucose levels are able to cause oxidative 
stress by various mechanisms, including glucose autoxidation, 
polyol pathway, advanced glycation end products formation, 
and PKCβ1/2 kinase.90 Increased free-radicals are able to attack 
unsaturated fatty acids oxidation in physiological systems. Obe-
sity and T2DM patients have increased amounts of some by-
products of lipid peroxidation, such as conjugated dienes and 
malondialdehyde.91
There are essential enzymes in antioxidant defense systems, 
such as glutathione reductase, glutathione S-transferase, and 
Fig. 4. 24 weeks of a high fat-diet causes decreases in adiponectin and adiponectin receptors and increases in HIF-1α in the brain. 8-week-old ICR 
mice were fed a 60% high fat diet for 24 weeks, and the levels of adiponectin, adipoR1 and HIF-1α were examined using western blot analysis. APN 
and adipoR1 were decreased in the cortices of the mice. HIF-1α increased in both the cortices and hippocampuses of the high fat-fed mice. Four 
mice were included in each group. *p<0.05. adipoR1, adiponectin receptor 1; HIF-1α, hypoxia inducible factor-1α; APN, adiponectin; HMW, high mo-
lecular weight; MMW, middle molecular weight; LMW, low molecular weight; ND, normal diet; HFD, high fat diet.
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glutathione disulfide.92 T2DM patients show high oxidative da-
mage and reduced antioxidant defenses mechanisms.93 Oxi-
dative stress induced by various conditions, including abnor-
mal superoxide dismutase and leaking mitochondria, is known 
to contribute to AD.94
In normal conditions, ROS is detoxified by producing succi-
nate95 via the stabilization of HIF-1α.96 When oxygen supply is 
adequate, mitochondrial lactate dehydrogenase in astrocytes is 
used to produce pyruvate and help in the synthesis of adenos-
ine triphosphate. However, under ROS stress, these detoxifica-
tion processes are unable to be effective. The process may lead 
towards lipid synthesis.97 Abnormal accumulation of lipid is 
commonly observed in patients with AD.98
Considering the noted relationships among obesity, T2DM, 
and AD, it is possible that increased ROS induced by metabolic 
alterations can cause AD pathologies (Fig. 5). There are several 
studies that demonstrate the effects of antioxidants on AD 
treatment. Various vitamins, such as Vitamin A, B, C, and K, are 
proven to be effective in AD treatment.99 We have also demon-
strated the effect of agmatine, a polyamine that works as an an-
tioxidant, on mice displaying AD like alterations induced by 
long term high-fat diet and rats with streptozotocin-induced 
AD.51,100 Oxidative stress is one of the most important factors in-
volved in the development and progression of AD. Using anti-
oxidants is a feasible approach that can help treat AD.
CONCLUSION
Conventional approaches to developing therapeutics for AD 
have focused on the Aβ hypothesis, which insists that Aβ causes 
AD pathologies. These approaches, however, have failed to 
treat or prevent AD. Through this review, we would like to sug-
gest that metabolites, such as insulin, adiponectin, and ROS, 
could be therapeutic targets for developing effective treatments 
for AD, considering that metabolic alterations may be the pri-
mary causes of the disease.
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